Latest News & Updates

Introducing: From the Desk of Dr. Heinz-Josef Lenz

Beginning in January, I will be blogging here at the C3 website.

I am a Gastrointestinal (GI) Oncologist at the University of Southern California (USC)/Norris Comprehensive Cancer Center. I am what people describe as a physician scientist, which means I do see patients and write a lot of clinical trials, but I also have a laboratory focusing on the molecular make up of tumors.

Posted by Heinz-Josef Lenz, MD on December 30th, 2008
Posted in: From the Desk of Dr. Lenz | 9 Comments »

Aspirin and Undigestible Starch Don’t Protect Against Lynch Syndrome

Neither daily aspirin or undigestible starch supplements reduced the risk for polyps and cancer for people with Lynch syndrome (also known as hereditary nonpolyposis colon cancer or HNPCC.)

Nearly 850 patients with identified Lynch syndrome were randomly assigned to receive aspirin, resistant starch, or placebos for up to four years. After an average of 2 years, 141 developed either precancerous polyps or cancer (neoplasia). There was no difference in either overall neoplasia or advanced neoplasia whether patients took aspirin or resistant starch or received a placebo. Continue reading…

Posted by Kate Murphy on December 29th, 2008
Posted in: Research & Treatment News | No Comments »
Tags: aspirin, fiber, Lynch syndrome

High Levels of Gene MACC1 Predicts Colorectal Cancer Spread

German scientists have identified a gene that has higher levels in colon cancer patients whose tumors are destined to spread. By initiating a signaling pathway in the cancer cell, MACC1 (Metastasis-Associated in Colon Cancer 1) promotes faster cell growth and cancer spread to distant sites in the body (metastasis) .

Their research was published online in Nature Medicine.

About a third of patients whose cancer is found in early stages will eventually have it spread to other organs. Measuring MACC1 may help doctors identify those patients, treat them more aggressively, and follow them more closely. Continue reading…

Posted by Kate Murphy on December 27th, 2008
Posted in: Research & Treatment News | No Comments »
Tags: colorectal cancer prognosis, molecular medicine

Boehringer Ingelheim Addresses Leucovorin Shortage

Boehringer Ingelheim, parent company of Bedford Laboratories, reports that Bedford is shipping some leucovorin, but that improvements in its manufacturing facilities will cause some short-term interruptions.

In a statement, Boehringer Ingleheim says that five lots of intravenous leucovorin were released between late November and mid-December, providing about 175,000 vials. Another two lots are expect to be shipped before the end of 2008 containing another 167,000 vials.

According to the statement,